Humana (NYSE:HUM) Given New $260.00 Price Target at Truist Financial

Humana (NYSE:HUM) had its price target decreased by analysts at Truist Financial from $280.00 to $260.00 in a report released on Wednesday,Benzinga reports. The firm currently has a “hold” rating on the insurance provider’s stock. Truist Financial’s target price suggests a potential upside of 16.24% from the company’s previous close.

Other research analysts have also recently issued research reports about the company. Guggenheim started coverage on Humana in a research note on Wednesday, April 9th. They issued a “buy” rating and a $326.00 price target on the stock. Mizuho raised their price objective on shares of Humana from $305.00 to $316.00 and gave the company an “outperform” rating in a research note on Wednesday, April 9th. Bank of America decreased their target price on shares of Humana from $320.00 to $260.00 and set a “neutral” rating for the company in a report on Tuesday, June 17th. Wall Street Zen cut shares of Humana from a “buy” rating to a “hold” rating in a report on Saturday, July 12th. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $290.00 price objective on shares of Humana in a research note on Thursday, May 1st. Seventeen investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, Humana presently has a consensus rating of “Hold” and a consensus target price of $279.81.

Humana Stock Performance

HUM opened at $223.68 on Wednesday. Humana has a 52-week low of $212.45 and a 52-week high of $406.46. The company has a market cap of $27.00 billion, a price-to-earnings ratio of 15.82, a PEG ratio of 1.55 and a beta of 0.44. The firm’s fifty day simple moving average is $235.46 and its two-hundred day simple moving average is $257.46. The company has a quick ratio of 1.91, a current ratio of 1.91 and a debt-to-equity ratio of 0.71.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, April 30th. The insurance provider reported $11.58 EPS for the quarter, topping analysts’ consensus estimates of $10.07 by $1.51. The firm had revenue of $32.11 billion during the quarter, compared to the consensus estimate of $32 billion. Humana had a net margin of 1.42% and a return on equity of 14.47%. The company’s revenue was up 8.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $7.23 earnings per share. Equities analysts anticipate that Humana will post 16.47 earnings per share for the current fiscal year.

Institutional Trading of Humana

A number of hedge funds have recently made changes to their positions in HUM. denkapparat Operations GmbH bought a new stake in shares of Humana during the fourth quarter valued at approximately $323,000. Allstate Corp bought a new position in shares of Humana during the fourth quarter valued at $905,000. Deutsche Bank AG boosted its position in shares of Humana by 18.2% during the fourth quarter. Deutsche Bank AG now owns 631,371 shares of the insurance provider’s stock valued at $160,185,000 after buying an additional 97,071 shares during the last quarter. Janney Montgomery Scott LLC bought a new stake in Humana in the 1st quarter worth about $1,309,000. Finally, Fred Alger Management LLC bought a new position in Humana during the 4th quarter valued at about $451,000. 92.38% of the stock is owned by institutional investors.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.